Squamous cell carcinoma is a most common malignant neoplasm of the oral cavity. The patient prognosis is still worse than that of all cancers combined, and the annual incidence of new cases is predicted to increase in the next few decades ([@bib8]; [@bib37]). Phenotypic alterations of carcinoma cells result from the aberrations of endogenous and exogenous factors, and select aggressive clones to progress carcinomas to the more advanced states. Understanding molecular mechanisms of carcinoma progression and developing the new therapeutic approach are prerequisite for the improvement of prognosis.

Oral carcinoma cells frequently inactivate tumour-suppressive proteins during the disease progression ([@bib8]). Our previous study demonstrated that mucosa-associated lymphoid tissue 1 (MALT1) is expressed in the nucleus of oral epithelial cells ([@bib7]) and substitutes keratins depending on its expression ([@bib15]). The advanced carcinomas inactivate MALT1 expression by the promoter methylation, and the loss of expression worse the patient prognosis ([@bib7]). However, nothing is known about the role of loss of expression in the carcinoma progression at present. The MALT1 is made up of three types of domain: a death domain, Ig-like domains, and a caspase-like domain. The B-cell or T-cell receptor antigen signals oligomerise MALT1 with BCL10 and CARMA1/3 into a CBM complex. The MALT1 interacts with BCL10 through its Ig-like domains and induces I*κ*B-kinase catalytic activity, resulting in nuclear factor-*κ*B (NF-*κ*B) activation in lymphocyte lineages ([@bib41]; [@bib21]). Unveiling gene data sets that are regulated by MALT1 substantiates the role of loss of expression in the carcinoma progression. In this study, we investigated the gene data sets and pathways by microarray analysis and determined the effect on carcinoma cell phenotype by migration assays.

Materials and methods
=====================

Cell lines
----------

HSC2 oral carcinoma cells, which marginally express *MALT1*, were obtained from the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer (Tohoku University, Sendai, Japan). HSC2 cells stably expressing FLAG-tagged full-length wild-type *MALT1* (~wtMALT1~HSC2 cells) and the NH~2~ terminal death and Ig-like domains-deleted dominant-negative MALT1 (~ΔMALT1~HSC2 cells; [@bib6]) and transfected vector alone (~mock~HSC2 cells) were established previously ([@bib7]). They were maintained in 10% fetal bovine serum and 100 units per ml of penicillin/streptomycin-containing DMEM (Sigma-Aldrich, St. Louis, MO, USA) in a conventional 5% CO~2~ incubator.

Microarray analysis
-------------------

Gene-expression profile was measured with RNA extracted from ~wtMALT1~HSC2 cells and ~mock~HSC2 cells and processed for aRNA synthesis, labelling, and hybridisation by Mitsubishi Chemical Mediscience, Inc. (Tokyo, Japan). First-strand cDNA synthesis with 100 ng of total RNA, synthesis of biotin-labelled aRNA, and clean up were carried out using GeneChip 3′IVT Express Kit (Affymetrix Japan, Tokyo, Japan). For hybridisation, 15 *μ*g of fragmented aRNA was incubated with GeneChip Human Genome U133A 2.0 in 250 *μ*l of hybridisation solution in GeneChip Hybridization Oven 640 (Affymetrix Japan) at 45 °C for 16 h. GeneChips were then washed and stained with GeneChip Fluidics Station 450 (Affymetrix Japan) according to manufacturer\'s instruction. Microarrays were scanned with GeneChip Scanner 3000 (Affymetrix Japan), and the signals were processed using GeneChip Command Console Software (AGCC, Affymetrix Japan). The scanned images were first assessed by visual inspection, then analysed to generate raw data files saved as CEL files using the default setting of AGCC. Robust Multichip Analysis was used to normalise the different arrays, and further analysis was carried out with GeneSpring GX10 (version 11.5.1, Agilent Technologies, Inc., Tokyo, Japan). Three replicates were used for microarray analysis and statistics. To find differentially expressed genes, we used Aspin-Welch\'s paired *t*-test and considered the significance when the *P*-value was below 0.05. The Benjamini--Hochberg false discovery rate (FDR) method was used to correct for multiple testing effect. Probe sets were considered to have changed qualitatively in a specific comparison if an adjusted *P*-value of 0.05 was obtained. Their normalised data were used to generate a list of differentially expressed genes between ~wtMALT1~HSC2 cells and ~mock~HSC2 cells when they had an absolute change of ⩾2-fold. Gene-expression changes that met these criteria were termed as 'significant RNA state change\' and had directional qualities of 'up\' or 'down\' (i.e., they can be upregulated or downregulated in ~wtMALT1~HSC2 cells). The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus ([@bib11]) and are accessible through GEO Series accession number GSE42335 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42335>).

Functional and pathway analyses of differentially expressed genes
-----------------------------------------------------------------

The differentially expressed gene list was ranked according to their fold changes and compared with sets of genes that were annotated according to the gene ontology (GO) for molecular function, cellular component, and biological process ([@bib2]). Results with *P*-value⩽0.05 and FDR were used identify canonical pathways associated with the differentially expressed genes by uploading the list into the Ingenuity Pathway Analysis (IPA) website (version 9.0, <http://www.ingenuity.com>). Briefly, the Ingenuity Knowledge base contains information from scientific publications regarding direct and indirect relationships between genes and proteins. Each identifier was mapped to its corresponding gene object in the Ingenuity knowledge base. These genes, called focus genes, were overlaid onto a global molecular network in the Ingenuity knowledge base. Networks of these focus genes were then algorithmically generated based on the information available in the IPA web site. All of the differentially expressed genes were included in the analysis, and ranked according to *P*-value ([@bib26]). In figures represented in this study, the upregulated genes were marked with red and the downregulated genes with green with the intensity of the colour being an indicator of the fold of expression.

Real-time PCR
-------------

Total RNA extracted from cell lines was reverse transcribed to cDNA by MultiScribe Reverse Transcriptase (Applied Biosystems, Foster City, CA, USA) and subjected to real-time PCR using the StepOne Real-time PCR system (Applied Biosystems). PCR conditions were 95 °C for 20 s followed by 40 cycles of 95 °C for 1 s and 60 °C for 20 s. The TaqMan probes (Applied Biosystems) specific for *LXN* (Hs00220138_m1), *TFF1* (Hs00907239_m1), *GATA3* (Hs00231122_m1), *TP53* (Hs01034249_m1), *CDH1* (Hs00170423_m1), *FABP4* (Hs01086177_m1), *FABP6* (Hs01031183_m1), *VEGFC* (Hs00153458_m1), *SNAI2* (Hs00950344_m1), *HMGA2* (Hs00171569_m1), *IL6ST* (Hs00174360_m1), *CDH2* (Hs00983062_m1), *PXN* (Hs01104424_m1), and *IL11* (Hs01055413_g1) were used. Expression levels were normalised against *ACTB* (TaqMan Endogenous Control Human *ACTB*, Applied Biosystems). Levels of gene expression (2^−*ΔΔ*Ct^) were determined by the standard curve method ([@bib32]).

Immunoblot
----------

Total cell lysates were used for the immunoblot with a standard protocol. The lysates in the SDS sample buffer containing 1 mℳ phenylmethanesulphonyl fluoride and a protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) were size fractionated by SDS--PAGE gels under reducing conditions and electrotransferred onto PVDF membranes. The membrane was probed with antibodies specific to TFF1, GATA3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), LXN (R&D Systems, Minneapolis, MN, USA), FABP4, FABP6, or *β*-actin (Sigma-Aldrich).

Wound-healing and migration assays
----------------------------------

Subconfluent cell monolayer (80--90% confluency) with or without *MALT1* short-interfering RNA (siRNA) transfection (50 nℳ; \#18601 siRNA; Ambion, Austin, TX, USA) was maintained in 1% fetal bovine serum-containing culture medium. Silencer Negative Control \#1 siRNA (Ambion) was used as a negative control. Wounds were created by the scratch using a pipettman tip and cultured up to 48 h. The wound closure was evaluated by measuring the width of the remaining wound ([@bib38]). The real-time cell electronic sensing assay based on electrical impedance readings in cell monolayers plated in wells containing built-in gold electrodes was performed. We have used the analyzer (xCELLigence RTCA-DP), 16-well e-plates and the integrated software (Roche Diagnostics GmbH). The RTCA System works by measuring the electronic impedance at the cell-sensor electrode interface integrated on the bottom of e-plates ([@bib49]). For time-lapse microscopy, ~wtMALT1~HSC2 cells, ~ΔMALT1~HSC2 cells, and ~mock~HSC2 cells were labelled with CellTracker Green Fluorescent Probe (Lonza, Walkersvill, MD USA) and seed onto 35-mm plastic dishes. After 10 h, the single cell migration was monitored using a laser scanning microscope (LSM 700; Carl Zeiss, Oberkochen, Germany) equipped with a transparent environmental chamber (Climabox, Carl Zeiss) under 5% CO~2~ in air at 37 °C. The microscope was driven by the IMARIS (Carl Zeiss) every 10 min during 16 h (*n*=4). Cell migration was characterised and quantified using an interactive tracking method ([@bib50]).

Statistical analysis
--------------------

Statistical analyses on the data manipulation for microarray analysis were indicated above. Percentage of wound closure and migration velocities was analysed by Wilcoxon test using JMP 7.0.1 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Genes regulated by MALT1
------------------------

Genes expressed in ~wtMALT1~HSC2 cells and ~mock~HSC2 cells were initially compared by the microarray analysis, and 2933 genes with a fold change of ⩾±2.0 and with the *P*\<0.05 were specified ([Figure 1A](#fig1){ref-type="fig"}). They included 1433 upregulated and 1500 downregulated genes in ~wtMALT1~HSC2 cells. Strict filtering of normalised intensity value with a fold change of ⩾±10.0 (415 probe sets) showed that the upregulated genes (*n*=328; fold change, 120.5±580.2, mean±s.d.) were more robustly changed than the downregulated genes (*n*=87, 21.2±16.0; *P*=0.002; [Figure 1B](#fig1){ref-type="fig"}). Top 10 for each was shown in [Table 1](#tbl1){ref-type="table"} (complete list was shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Validation of microarray data
-----------------------------

Quantitative real-time PCR was done to validate the genes expressed at various levels, and confirmed the expression in an almost same pattern of the microarray analysis ([Figure 1C](#fig1){ref-type="fig"}). The differential protein expression encoded by representative genes that suppress (*LXN*, *TFF1*, and *GATA3*) and stimulate (*FABP4* and *FABP6*) carcinoma progression ([@bib28]; [@bib16]; [@bib19]; [@bib27]; [@bib39]) was substantiated at the protein level ([Figure 1D](#fig1){ref-type="fig"}). Although expression of other genes was not validated in this study, many of downregulated genes associate with oral carcinoma progression such as *TWIST1*, *LMO4*, *ZEB2*, *WNT3*, and *MMP14* ([@bib36]; [@bib24]; [@bib45]; [@bib20]; [@bib29]).

GO and pathway analyses
-----------------------

To analyse the function of MALT1-responsive genes, all data sets of genes were first evaluated by the GO analysis. It suggested that the genes are involved in inter- and intra-cellular signalling, cellular organisation, and developmental processes ([Table 2](#tbl2){ref-type="table"}). The IPA top three bio-functions were 'Cancer\', 'Cellular Movement\', and 'Gastrointestinal Disease\', and canonical pathways were 'HER2-Signalling in Breast Cancer\', 'Glioma Invasiveness Signalling\', and 'Role of Tissue Factor in Cancer\' ([Figure 2](#fig2){ref-type="fig"}). The list with *P*\<0.05 and threshold value of −log(*P*-value), 0.05, were summarised in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Other classification of our interests that were not included in the GO analysis but closely correlated with carcinoma progression including extracellular matrix-degrading enzymes, collagens, laminins, integrins, WNT pathways, and cancer and/or epidermal stem cell markers were listed in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}.

The pathway analysis was performed on all genes identified with an absolute change of ⩾2-fold. Since the IPA showed a most close association of the gene data sets to 'Cancer\', we overviewed 'Molecular Mechanisms of Cancer\' to identify the signalling pathway network affected by MALT1. Ras and SMAD pathways occupied central positions in the network ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). ErbB1 and its ligands (AREG, TGF-*α*, EREG, and NRG1) and signalling molecules (RAS, PI3K, and PKC) listed in 'ErbB Signalling\' were downregulated ([Figure 3A](#fig3){ref-type="fig"}). TGF-*β* pathway genes for TGF-*β*, TGF-*β* receptor II, and Smad-2/3/4 ([Figure 3B](#fig3){ref-type="fig"}) and many FAK signalling genes, including *ITGs*, *EGFR*, *RHAMM*, *VCL*, *PXN*, and *DOCKs*, were downregulated ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Although MALT1 is well known to activate NF-*κ*B in lymphocyte lineages ([@bib21]), there was no definite predisposition for genes involved in NF-*κ*B activation ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Enhanced migration by loss of MALT1 expression
----------------------------------------------

The IPA bio-function analysis suggested a close association of MALT1 in 'Cellular Movement\', and enhanced migration is a representative phenomenon of the aggressive behaviours of carcinoma cells ([@bib12]). Therefore, migration of ~wtMALT1~HSC2 and ~ΔMALT1~HSC2 cells was compared with that of ~mock~HSC2 cells by several sets of experiments. The conventional monolayered wound-healing assay on slide glasses showed 80.5% reduction in wound closure by ~wtMALT1~HSC2 cells and the 185.0% enhancement by ~ΔMALT1~HSC2 cells compared with the ~mock~HSC2 cells ([Figure 4A and B](#fig4){ref-type="fig"}). The siRNA against *MALT1* facilitated the ~wtMALT1~HSC2 cell wound closure (*P*=0.003; [Figure 4C](#fig4){ref-type="fig"}; [Supplementary Table 4](#sup1){ref-type="supplementary-material"}). The ~ΔMALT1~HSC2 cells did not respond to the siRNA because of the lack of binding site in its gene construct. To quantify it more accurately and continuously, the real-time wound-healing assay using the RTCA-DP system was performed. As shown in [Figure 4D](#fig4){ref-type="fig"}, the enhanced wound coverage by ~ΔMALT1~HSC2 cells (218.6%) and the reduction by ~wtMALT1~HSC2 cells (66.4%) were confirmed. Since the wound closure reflects many aspects of cells ([@bib48]), single cell migration was evaluated by the time-lapse analysis ([Figure 4E](#fig4){ref-type="fig"}). Migration velocities of ~mock~HSC2 cells were 1.01±0.05 *μ*m h^−1^. The ~ΔMALT1~HSC2 cells markedly quicken the velocities to 3.06±0.60 *μ*m h^−1^ (*P*=0.021), and ~wtMALT1~HSC2 cells almost unmoved for 16 h (0.21±0.01 *μ*m h^−1^; *P*=0.021).

Discussion
==========

A well-established role of NF-*κ*B activation by MALT1 in lymphocytes and enhanced NF-*κ*B activity in advanced oral carcinomas intimate that MALT1 promotes the carcinoma progression ([@bib25]; [@bib21]). However, MALT1 is expressed in normal oral epithelial cells and the loss of expression closely associates with the worse prognosis of carcinoma patients ([@bib7]). Then, we hypothesised that MALT1 has the differential role between epithelial cells and lymphocyte lineages, and analysed gene data sets that were affected by MALT1 in oral carcinoma cells to gain insights into this paradox. Most of the genes registered in 'NF-*κ*B Signalling\' in the IPA pathway database were unaffected or downregulated by MALT1, and the upregulated were limited to three genes (data not shown) among the 54 NF-*κ*B-induced genes in head and neck carcinoma cells that were previously reported ([@bib9]). Comparative analysis using IPA demonstrated that the genes downregulated by MALT1 affect EGF and TGF-*β* pathways and cellular movement, suggesting the stimulation of oral carcinoma aggressiveness by loss of MALT1 expression.

*EGFR* encoding EGFR (ErbB1, HER-1), a most predominant EGF receptor in head and neck carcinomas ([@bib3]), was downregulated. Although other EGF receptors (ErbB2--4) were upregulated, their expression and pathological role in head and neck carcinomas are a controversial issue ([@bib33]; [@bib4]; [@bib51]). The EGFR ligands, *AREG*, *TGFA*, and *EREG* downregulated by MALT1, are overexpressed in oral carcinomas and stimulate proliferation of carcinoma cells ([@bib31]; [@bib44]; [@bib35]). Mucosa-associated lymphoid tissue 1 also downregulated EGF signalling molecules, RAS (*HRAS* and *NRAS*) and PKC (*PKCA*, *PKCI*, and *PKCQ*). The amplification of *EGFR* loci *per se* attributes to oral carcinoma development and progression ([@bib34]), and EGFR-mediated pathway is strongly activated in an aggressive subset of oral carcinoma with worse prognosis ([@bib1]). Although the frequency of *EGFR* active mutation in oral carcinomas is controversial ([@bib14]; [@bib22]), MALT1 may negatively regulate the pathway by the suppression of gene expression regardless of the presence or absence of mutation. These data suggest the liberation of EGF-EGFR pathway from the suppression upon loss of MALT1 expression.

In parallel with the suppressive role for EGF signalling gene expression, MALT1 downregulated *TGFB2*, *TGFBR2*, *SMAD2*, *SMAD3*, and *SMAD4*. A protein complex made of these SMADs is crucial for the TGF-*β*-TGFBR2 signal transduction ([@bib30]). Although TGF-*β* acts as a potent tumour suppressor at the early stage of carcinoma progression, it stimulates cell proliferation, invasion, metastasis, and angiogenesis at the late stage ([@bib30]). Loss of MALT1 expression occurs at the late stage of oral carcinoma progression ([@bib7]). Mucosa-associated lymphoid tissue 1 also downregulated genes encoding gp130 (*IL6ST*) and IL-11 (*IL11*), which stimulate carcinoma progression under the TGF-*β* pathway ([@bib5]). These data imply that the loss of expression facilitates oral carcinomas to activate TGF-*β* signalling and pathway at the late stage of progression.

Since EGF and TGF-*β* signalling frequently interact each other and co-regulate gene expression that enhance aggressive phenotypes of carcinoma cells ([@bib17]; [@bib46]; [@bib10]), it is difficult to discern which signalling has a principal effect on the target gene expression in ~wtMALT1~HSC2 cells. Of note, a mesenchyme-specific transcriptional factor, *HMGA2*, that is upregulated by these signalling induces epithelial--mesenchymal transition (EMT) in carcinoma cells ([@bib18]; [@bib43]). Induction of the EMT gains carcinomas invasive and chemo-resistant properties ([@bib48]; [@bib12]). HMGA2 is predominantly expressed at invasive front oral carcinoma cells showing the EMT and in the patients with worse prognosis ([@bib23]), and MALT1 expression rapidly declines at the invasive front carcinoma cells ([@bib7]). HMGA2 represses *CDH1* expression through *SNAI2*, *ZEB2*, and *TWIST1* ([@bib18]; [@bib42]), which were downregulated in ~wtMALT1~HSC2 cells. As numbers of previous studies established a fact that inactivation of E-cadherin (*CDH1*) expression is a critical determinant for aggressive carcinomas ([@bib12]; [@bib13]), expression status of MALT1 may have a great impact on oral carcinoma progression.

Mucosa-associated lymphoid tissue 1 also suppressed other EMT inducers (WNT3, FGFs, PDGFs, IL6R, and FGFRs) and related genes encoding FAK signalling (integrins and paxillin), extracellular matrix-degrading enzymes (MMPs, ADAMs, plasminogen activators, kallikreins and cathepsins), CD44, SPARC, collagens, laminins, Jagged2, and podoplanin ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). It appears likely that loss of MALT1 expression activate the EMT machinery.

Enhanced migration is one of most representative characteristics of the EMT ([@bib48]; [@bib12]). Strong suppression of the migration by MALT1 supports our hypothesis that MALT1 has a distinct role in oral carcinoma cells from lymphoma cells. Since TGF-*β* and EGF pathways synergistically accelerate the EMT and migration of carcinoma cells, their liberation from the suppression by MALT1 may have a key readout circuitry in oral carcinoma progression. Detailed analysis for the role of MALT1 on the pathways should contribute to understand the pathology of oral carcinomas and to develop novel therapeutic strategies for the carcinoma patients.
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![**Microarray analysis and its validation by real-time PCR and immunoblot.** Log2 fold-change (FC) and their corresponding --log10(*P*-value) of all genes in the microarray were taken for construction of the volcano plot. Genes upregulated and downregulated \>2.0-fold change with a *P*-value of \<0.05 were depicted in light red and green, respectively. All other genes that were not significantly altered were in black (**A**). Normalised intensity value of gene data set in ~mock~HSC2 cells (m) and ~wtMALT1~HSC2 cells (w) with different FCs (i, ⩾2.0; ii, ⩾4.0; iii, ⩾10.0) was illustrated. Genes upregulated and downregulated in ~wtMALT1~HSC2 cells were depicted in blue and red, respectively (**B**). Expression of genes of interests was analysed by quantitative real-time PCR (*n*=3). FC of genes of interests in ~wtMALT1~HSC2 cells relative to ~mock~HSC2 cells were standardised by the expression of *ACTB* (**C**). Protein expression was examined by the immunoblot. *β*-actin was used as an internal control (**D**).](bjc2013307f1){#fig1}

![**Ingenuity pathway analysis of the genes.** The significance of each function or canonical pathway was determined based on the *P*-value by right-tailed Fisher\'s exact test and with threshold \<0.05. The top 15 possible bio-functions (**A**) and canonical pathways (**B**) of genes regulated by MALT1 were shown. Ratio of number of genes in a given pathway satisfying the cutoff and total number of genes present in those pathways was determined by the pathway analysis.](bjc2013307f2){#fig2}

![**'ErbB signalling\' and 'TGF-*β* pathway\' in the canonical pathway.** Functional interacting network among gene data sets was uploaded in the Ingenuity Pathway Analysis tool and the network of 'ErbB Signalling (**A**)\' and 'TGF-*β* pathway (**B**)\'. Genes from our data set and falling in this network were shown in either red (upregulated) or green (downregulated).](bjc2013307f3){#fig3}

![**Migration of carcinoma cells.** (**A**) Knock-down of MALT1 protein expression in ~wtMALT1~HSC2 cells and ~ΔMALT1~HSC2 cells by the siRNA against *wtMALT1*. The protein expression was probed by the immunoblotting using an anti-FLAG antibody. (**B**) Migration of cells 24 h after injury in the presence or absence of 50 nℳ *MALT1* siRNA. White broken lines represent the original wound edges. Scale bar=1 mm. (**C**) Percentage of wound closure at 24 h. The graph indicates means±s.d. of wound closure at 24 h (*n*=5). \**P*\<0.001 (compared with mock+siRNA) and \*\**P*\<0.005 (compared with wtMALT1 without siRNA). (**D**) Real-time sensing wound-healing assay. The coverage of wounds was monitored by the xCELLigence system until 14 h after injury. (**E**) Representative examples of ~wtMALT1~HSC2 (wtMALT1), ~ΔMALT1~HSC2 (ΔMALT1), and ~mock~HSC2 (mock) cell migration for 16 h using time-lapse microscopy (*n*=4). Scale bar=50 *μ*m.](bjc2013307f4){#fig4}

###### Top 20 genes altered in ~wtMALT1~HSC2 cells

  **Gene symbol**          **FC**   **Gene description**
  ------------------------ -------- ------------------------------------------------------------------------------
  **Upregulated**                   
  JUP///KRT19              9943.8   Junction plakoglobin///keratin 19
  LXN                      2407.5   Latexin
  TFF1                     1377.1   Trefoil factor 1
  CXCR4                    1196.5   Chemokine (C-X-C motif) receptor 4
  SH3YL1                   1113.9   SH3 domain containing, Ysc84-like 1
  SERPINA3                 748.3    Serpin peptidase inhibitor, clade A
  TARP///TRBC2             726.8    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2
  TBL1X                    721.5    Transducin (beta)-like 1X-linked
  TARP                     597.5    TCR gamma alternate reading frame protein
  ATP2A3                   523.3    ATPase, Ca++ transporting, ubiquitous
  **Downregulated**                 
  CYBRD1                   97.0     Cytochrome b reductase 1
  PSMB8                    73.3     Proteasome subunit, beta type, 8
  FABP4                    64.6     Fatty acid binding protein 4, adipocyte
  HOXD10                   61.6     Homeobox D10
  SERPINB13                60.5     Serpin peptidase inhibitor, clade B, member 13
  FABP6                    53.4     Fatty acid binding protein 6, ileal
  SERPINB2                 52.6     Serpin peptidase inhibitor, clade B, member 2
  TMPRSS11E///TMPRSS11E2   43.9     Transmembrane protease, serine 11E///transmembrane protease, serine 11E2
  PPP4R4                   39.2     Protein phosphatase 4, regulatory subunit 4
  BCL11A                   39.1     B-cell CLL/lymphoma 11A

Abbreviations: CLL=chronic lymphocytic leukemia; FC=fold change; TCR=T-cell receptor.

###### Classification of gene sets by GO analysis

  **Category**                                    **Total gene**   **Genes/input**    ***P*-value**
  ----------------------------------------------- ---------------- ----------------- ---------------
  Nucleosome                                      86               43                   4.71E−12
  Protein--DNA complex                            105              43                    3.55E−5
  Chromatin                                       185              52                    2.60E−6
  Basolateral plasma membrane                     146              24                    1.03E−5
  Protein--DNA complex assembly                   112              46                   2.79E−10
  Nucleosome assembly                             107              46                   5.77E−10
  Chromatin assembly                              108              46                    8.37E−5
  Protein--DNA complex subunit organisation       117              46                    1.66E−9
  Nucleosome organisation                         114              46                    6.78E−9
  DNA packaging                                   131              46                    4.09E−4
  Anatomical structure morphogenesis              811              26                    3.77E−4
  Anatomical structure development                1885             56                    5.26E−8
  Tissue development                              500              31                    7.63E−8
  Epidermis development                           133              29                    2.00E−4
  System development                              1565             29                    3.23E−7
  Cellular component assembly at cellular level   459              46                    4.76E−7
  Cellular component assembly                     677              46                    4.85E−7
  DNA conformation change                         150              46                    7.12E−7
  Multicelluar organismal development             2064             162                   9.95E−7
  Organ development                               1090             29                    1.41E−6
  Developmental process                           2336             184                   1.88E−6
  Chromatin assembly or disassembly               150              49                    4.28E−6
  Pathogenesis                                    21               13                    6.91E−6
  Homophilic cell adhesion                        114              39                    1.19E−5
  Cell--cell adhesion                             235                                        

Abbreviation: GO=gene ontology.
